• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

人源化抗肝细胞生长因子单克隆抗体（YYB-101）抑制卵巢癌进展。

Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression.

作者信息

Kim Hyun Jung, Lee Sukmook, Oh Yong-Seok, Chang Ha Kyun, Kim Young Sang, Hong Sung Hee, Kim Jung Yong, Park Young-Whan, Lee Song-Jae, Song Seong-Won, Kim Jung Ju, Heo Kyun

机构信息

Research Institute, National Cancer Center, Goyang-si, South Korea.

Department of Bioinspired Science, Ewha Womans University, Seoul, South Korea.

出版信息

Front Oncol. 2019 Jul 9;9:571. doi: 10.3389/fonc.2019.00571. eCollection 2019.

DOI:10.3389/fonc.2019.00571
PMID:31355133
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6631954/
Abstract

Current chemotherapy regimens have certain limitations in improving the survival rates of patients with advanced ovarian cancer. Hepatocyte growth factor (HGF) is important in ovarian cancer cell migration and invasion. This study assessed the effects of YYB-101, a humanized monoclonal anti-HGF antibody, on the growth and metastasis of ovarian cancer cells. YYB-101 suppressed the phosphorylation of the HGF receptor c-MET and inhibited the migration and invasion of SKOV3 and A2780 ovarian cancer cells. Moreover, the combination of YYB-101 and paclitaxel synergistically inhibited tumor growth in an ovarian cancer mouse xenograft model and significantly increased the overall survival (OS) rate compared with either paclitaxel or YYB-101 alone. Taken together, these findings suggest that YYB-101 has therapeutic potential in ovarian cancer when combined with conventional chemotherapy agents.

摘要

目前的化疗方案在提高晚期卵巢癌患者生存率方面存在一定局限性。肝细胞生长因子（HGF）在卵巢癌细胞迁移和侵袭过程中起重要作用。本研究评估了人源化抗HGF单克隆抗体YYB-101对卵巢癌细胞生长和转移的影响。YYB-101可抑制HGF受体c-MET的磷酸化，并抑制SKOV3和A2780卵巢癌细胞的迁移和侵袭。此外，在卵巢癌小鼠异种移植模型中，YYB-101与紫杉醇联合使用可协同抑制肿瘤生长，与单独使用紫杉醇或YYB-101相比，显著提高了总生存率（OS）。综上所述，这些发现表明，YYB-101与传统化疗药物联合使用时在卵巢癌治疗中具有潜在疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/0ef9a70513c2/fonc-09-00571-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/e6a48a9db98e/fonc-09-00571-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/2fa665fbf49e/fonc-09-00571-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/6e83ccfac467/fonc-09-00571-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/8a7abf4e09a9/fonc-09-00571-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/60bd45f2a048/fonc-09-00571-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/0ef9a70513c2/fonc-09-00571-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/e6a48a9db98e/fonc-09-00571-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/2fa665fbf49e/fonc-09-00571-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/6e83ccfac467/fonc-09-00571-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/8a7abf4e09a9/fonc-09-00571-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/60bd45f2a048/fonc-09-00571-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/6631954/0ef9a70513c2/fonc-09-00571-g0006.jpg

相似文献

1
Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression.人源化抗肝细胞生长因子单克隆抗体（YYB-101）抑制卵巢癌进展。
Front Oncol. 2019 Jul 9;9:571. doi: 10.3389/fonc.2019.00571. eCollection 2019.
2
YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation.YYB-101，一种人源化抗肝细胞生长因子单克隆抗体，抑制卵巢癌细胞迁移和增殖。
Anticancer Res. 2021 Feb;41(2):671-678. doi: 10.21873/anticanres.14818.
3
Preclinical development of a humanized neutralizing antibody targeting HGF.一种靶向肝细胞生长因子的人源化中和抗体的临床前开发
Exp Mol Med. 2017 Mar 24;49(3):e309. doi: 10.1038/emm.2017.21.
4
Inhibition of tumor growth in a mouse xenograft model by the humanized anti-HGF monoclonal antibody YYB-101 produced in a large-scale CHO cell culture.在大规模 CHO 细胞培养中生产的人源化抗 HGF 单克隆抗体 YYB-101 抑制小鼠异种移植模型中的肿瘤生长。
J Microbiol Biotechnol. 2013 Sep 28;23(9):1327-38. doi: 10.4014/jmb.1306.06007.
5
[Effect of hepatocyte growth factor on invasion of ovarian cancer cell line SKOV3 and its signal transduction pathway].[肝细胞生长因子对卵巢癌细胞系SKOV3侵袭及其信号转导通路的影响]
Ai Zheng. 2006 May;25(5):570-5.
6
Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.对肝细胞生长因子具有治疗潜力的全人源单克隆抗体，可对抗依赖肝细胞生长因子/c-Met的人类肿瘤。
Cancer Res. 2006 Feb 1;66(3):1721-9. doi: 10.1158/0008-5472.CAN-05-3329.
7
The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.肝细胞生长因子在体内使卵巢癌细胞对顺铂和紫杉醇敏感的治疗潜力。
Clin Cancer Res. 2007 Apr 1;13(7):2191-8. doi: 10.1158/1078-0432.CCR-06-1915.
8
HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor.热休克蛋白 27 对于肝细胞生长因子触发的侵袭和转移是必需的。
Int J Cancer. 2014 Mar 15;134(6):1289-99. doi: 10.1002/ijc.28464. Epub 2013 Sep 18.
9
A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.一种新型兔抗肝细胞生长因子单克隆中和抗体可抑制前列腺癌细胞和小鼠异种移植瘤的生长。
Biochem Biophys Res Commun. 2015 Aug 14;464(1):154-60. doi: 10.1016/j.bbrc.2015.06.107. Epub 2015 Jun 18.
10
Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma.鉴定基因组和分子特征，这些特征使胶质母细胞瘤对 HGF 靶向治疗具有治疗敏感性。
Neuro Oncol. 2019 Feb 14;21(2):222-233. doi: 10.1093/neuonc/noy105.

引用本文的文献

1
Identification and validation of IRF6 related to ovarian cancer and biological function and prognostic value.鉴定和验证与卵巢癌相关的 IRF6 及其生物学功能和预后价值。
J Ovarian Res. 2024 Mar 16;17(1):64. doi: 10.1186/s13048-024-01386-4.
2
Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting.针对 HGF/c-MET 靶向的卵巢癌治疗策略。
Medicina (Kaunas). 2022 May 11;58(5):649. doi: 10.3390/medicina58050649.
3
Dependence receptors: new targets for cancer therapy.依赖受体：癌症治疗的新靶点。

本文引用的文献

1
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
2
Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer.在卵巢癌临床前模型中，克唑替尼与顺铂具有协同作用。
Am J Transl Res. 2017 Apr 15;9(4):1667-1679. eCollection 2017.
3
Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.肝细胞生长因子，肿瘤微环境中的关键促肿瘤因子。
EMBO Mol Med. 2021 Nov 8;13(11):e14495. doi: 10.15252/emmm.202114495. Epub 2021 Sep 20.
4
Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.卵巢癌患者血清中 HGF 水平的纵向变化与预后的相关性。
Mol Oncol. 2021 Dec;15(12):3626-3638. doi: 10.1002/1878-0261.12949. Epub 2021 Apr 2.
5
HGF/MET Signaling in Malignant Brain Tumors.HGF/MET 信号在恶性脑肿瘤中的作用。
Int J Mol Sci. 2020 Oct 13;21(20):7546. doi: 10.3390/ijms21207546.
6
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients.抗肝细胞生长因子抗体（YYB101）在难治性实体瘤患者中的首次人体I期试验。
Ther Adv Med Oncol. 2020 Jun 2;12:1758835920926796. doi: 10.1177/1758835920926796. eCollection 2020.
Cancers (Basel). 2017 Apr 17;9(4):35. doi: 10.3390/cancers9040035.
4
Preclinical development of a humanized neutralizing antibody targeting HGF.一种靶向肝细胞生长因子的人源化中和抗体的临床前开发
Exp Mol Med. 2017 Mar 24;49(3):e309. doi: 10.1038/emm.2017.21.
5
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.新诊断晚期卵巢癌的新辅助化疗：妇科肿瘤学会和美国临床肿瘤学会临床实践指南
Gynecol Oncol. 2016 Oct;143(1):3-15. doi: 10.1016/j.ygyno.2016.05.022. Epub 2016 Aug 8.
6
Therapeutic targeting of tetraspanin8 in epithelial ovarian cancer invasion and metastasis.治疗性靶向四跨膜蛋白 8 抑制上皮性卵巢癌侵袭和转移
Oncogene. 2016 Aug 25;35(34):4540-8. doi: 10.1038/onc.2015.520. Epub 2016 Jan 25.
7
Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum.卵巢癌细胞分泌的肝细胞生长因子通过腹膜间皮-间充质转化刺激腹膜种植。
Gynecol Oncol. 2015 Nov;139(2):345-54. doi: 10.1016/j.ygyno.2015.08.010. Epub 2015 Aug 31.
8
INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models.INC280是一种口服可用的c-MET小分子抑制剂，可降低卵巢癌细胞模型中的迁移和黏附能力。
Sci Rep. 2015 Jul 3;5:11749. doi: 10.1038/srep11749.
9
Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF.人源化抗肝细胞生长因子（HGF）抗体可抑制成纤维细胞衍生的HGF诱导的伊立替康（CPT-11）天然耐药性。
Oncotarget. 2015 Sep 15;6(27):24047-60. doi: 10.18632/oncotarget.4369.
10
Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.卵巢癌腹水通过 HGF 依赖性和非依赖性机制通过 cMet 途径增强患者来源的腹膜间皮细胞的迁移。
Int J Cancer. 2015 Jul 15;137(2):289-98. doi: 10.1002/ijc.29385. Epub 2014 Dec 18.